Conavi Medical to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
Conavi Medical (TSXV: CNVI) (OTCQB: CNVIF), a commercial stage medical device company specializing in imaging technologies for minimally invasive cardiovascular procedures, has announced its participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference.
CEO Thomas Looby will present on Tuesday, May 6, 2025, at 3:00 p.m. Eastern Time at the Metro Toronto Convention Centre. The presentation will be accessible via webcast, with replay available for 90 days on Conavi's Investor Relations website.
The conference facilitates connections between U.S., Canadian, and international investors interested in Canadian healthcare sector developments, offering corporate updates through presentations and private meetings with leading public and private companies.
Conavi Medical (TSXV: CNVI) (OTCQB: CNVIF), un'azienda di dispositivi medici in fase commerciale specializzata in tecnologie di imaging per procedure cardiovascolari minimamente invasive, ha annunciato la sua partecipazione alla Conferenza degli Investitori nel Settore Sanitario 2025 di Bloom Burton & Co.
Il CEO Thomas Looby presenterà martedì 6 maggio 2025 alle 15:00 ora orientale presso il Metro Toronto Convention Centre. La presentazione sarà accessibile tramite webcast, con una replica disponibile per 90 giorni sul sito web delle Relazioni con gli Investitori di Conavi.
La conferenza favorisce il collegamento tra investitori statunitensi, canadesi e internazionali interessati agli sviluppi del settore sanitario canadese, offrendo aggiornamenti aziendali attraverso presentazioni e incontri privati con importanti società pubbliche e private.
Conavi Medical (TSXV: CNVI) (OTCQB: CNVIF), una empresa de dispositivos médicos en etapa comercial especializada en tecnologías de imagen para procedimientos cardiovasculares mínimamente invasivos, ha anunciado su participación en la Conferencia de Inversionistas en Salud 2025 de Bloom Burton & Co.
El CEO Thomas Looby presentará el martes 6 de mayo de 2025 a las 3:00 p.m. hora del Este en el Metro Toronto Convention Centre. La presentación estará disponible vía webcast, con repetición accesible durante 90 días en el sitio web de Relaciones con Inversionistas de Conavi.
La conferencia facilita la conexión entre inversionistas de EE. UU., Canadá e internacionales interesados en el desarrollo del sector salud canadiense, ofreciendo actualizaciones corporativas mediante presentaciones y reuniones privadas con empresas públicas y privadas líderes.
Conavi Medical (TSXV: CNVI) (OTCQB: CNVIF)는 최소 침습 심혈관 시술을 위한 영상 기술을 전문으로 하는 상업 단계 의료기기 회사로, 2025년 Bloom Burton & Co. 헬스케어 투자자 컨퍼런스에 참여한다고 발표했습니다.
CEO 토마스 루비는 2025년 5월 6일 화요일 동부 표준시 기준 오후 3시에 토론토 메트로 컨벤션 센터에서 발표할 예정입니다. 발표는 웹캐스트를 통해 시청할 수 있으며, 컨퍼런스 종료 후 90일간 Conavi 투자자 관계 웹사이트에서 다시보기 가능합니다.
이 컨퍼런스는 미국, 캐나다 및 국제 투자자들이 캐나다 헬스케어 부문의 발전에 관심을 가지고 연결할 수 있도록 지원하며, 주요 상장 및 비상장 기업들과의 프레젠테이션 및 비공개 미팅을 통해 기업 업데이트를 제공합니다.
Conavi Medical (TSXV : CNVI) (OTCQB : CNVIF), une société de dispositifs médicaux en phase commerciale spécialisée dans les technologies d'imagerie pour les procédures cardiovasculaires mini-invasives, a annoncé sa participation à la Conférence des investisseurs en santé 2025 de Bloom Burton & Co.
Le PDG Thomas Looby présentera le mardi 6 mai 2025 à 15h00, heure de l'Est au Metro Toronto Convention Centre. La présentation sera accessible via webcast, avec une rediffusion disponible pendant 90 jours sur le site des relations investisseurs de Conavi.
La conférence facilite les connexions entre investisseurs américains, canadiens et internationaux intéressés par les développements du secteur de la santé au Canada, offrant des mises à jour d'entreprise via des présentations et des réunions privées avec des entreprises publiques et privées de premier plan.
Conavi Medical (TSXV: CNVI) (OTCQB: CNVIF), ein medizinisches Geräteunternehmen in der kommerziellen Phase, das sich auf Bildgebungstechnologien für minimalinvasive kardiovaskuläre Verfahren spezialisiert hat, hat seine Teilnahme an der 2025 Bloom Burton & Co. Healthcare Investor Conference angekündigt.
CEO Thomas Looby wird am Dienstag, den 6. Mai 2025, um 15:00 Uhr Eastern Time im Metro Toronto Convention Centre präsentieren. Die Präsentation wird per Webcast zugänglich sein, mit einer Wiederholung, die für 90 Tage auf der Investor-Relations-Website von Conavi verfügbar ist.
Die Konferenz ermöglicht Verbindungen zwischen US-amerikanischen, kanadischen und internationalen Investoren, die an Entwicklungen im kanadischen Gesundheitssektor interessiert sind, und bietet Unternehmensupdates durch Präsentationen und private Treffen mit führenden börsennotierten und privaten Unternehmen.
- None.
- None.
Toronto, Ontario--(Newsfile Corp. - April 25, 2025) - Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) ("Conavi" or the "Company"), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, today announced that Thomas Looby, CEO of Conavi Medical, will present and participate in one-on-one meetings at the 2025 Bloom Burton & Co. Healthcare Investor Conference being held in Toronto on May 5-6, 2025.
Details on the presentation are as follows:
Date: Tuesday, May 6, 2025
Time: 3:00 p.m. Eastern Time
Location: Metro Toronto Convention Centre, Toronto
Webcast: https://event.summitcast.com/view/hG2KhRan38C8o5wZiWyxNK/cnYwKD5CoHUUJVeVinaQyE
Webcast and replay information for this event will also be available on the Investor Relations section of Conavi's website at https://www.conavi.com/novasight/investor-information . The replay will be available for 90 days.
The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from premier Canadian publicly traded and private companies through presentations and private meetings. For more information, please visit: bloomburton.com/conference.
About Conavi Medical
Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first system to combine both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid System has 510(k) clearance from the U.S. Food and Drug Administration; and regulatory approval for clinical use from Health Canada, China's National Medical Products Administration, and Japan's Ministry of Health, Labor and Welfare. For more information, visit conavi.com.
Notice on forward-looking statements:
This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Conavi and its business, which may include, but are not limited to, statements with respect to the anticipated use of proceeds from the Offering. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are "forward-looking information or statements". Often but not always, forward-looking information or statements can be identified by the use of words such as "shall", "intends", "anticipate", "believe", "plan", "expect", "intend", "estimate" "anticipate" or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "might", "can", "could", "would" or "will" be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, those listed in the "Risk Factors" section of the short form prospectus dated April 15, 2025 and the joint information circular of the Company dated August 30, 2024 (both of which are on the Company's profile at www.sedarplus.ca). Although Conavi has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Conavi does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
CONTACT:
Stefano Picone
Chief Financial Officer
(416) 483-0100
No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/249665
FAQ
When and where will Conavi Medical (CNVIF) present at the 2025 Bloom Burton Healthcare Conference?
How can investors access Conavi Medical's (CNVIF) presentation at the Bloom Burton Conference?
How long will the replay of Conavi Medical's (CNVIF) Bloom Burton Conference presentation be available?
What is the focus of Conavi Medical's (CNVIF) business operations?
What type of investors does the 2025 Bloom Burton Healthcare Conference target?
